Orchestra BioMed to Receive Up to $21 Million from Vivasure Sale to Haemonetics
I'm PortAI, I can summarize articles.
Orchestra BioMed Holdings Inc. is set to receive up to $21 million from the sale of its strategic holding, Vivasure Medical Limited, to Haemonetics Corporation. The company expects $11 million in cash proceeds in 2026, including $5 million upfront and $6 million as a milestone payment. Additional earnings will come from future revenue based on milestone achievements. Orchestra BioMed has significantly contributed to Vivasure’s development, particularly in its PerQseal technology.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments